KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $5.1 million.

  • Aquestive Therapeutics' Accumulated Expenses rose 204.98% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 204.98%. This contributed to the annual value of $5.9 million for FY2024, which is 908.11% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Accumulated Expenses stood at $5.1 million, which was up 204.98% from $5.0 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Accumulated Expenses high stood at $8.7 million for Q4 2021, and its period low was $3.3 million during Q1 2025.
  • For the 5-year period, Aquestive Therapeutics' Accumulated Expenses averaged around $5.9 million, with its median value being $5.7 million (2024).
  • Per our database at Business Quant, Aquestive Therapeutics' Accumulated Expenses soared by 23027.48% in 2021 and then tumbled by 3946.32% in 2023.
  • Aquestive Therapeutics' Accumulated Expenses (Quarter) stood at $8.7 million in 2021, then fell by 8.8% to $8.0 million in 2022, then fell by 18.45% to $6.5 million in 2023, then dropped by 9.08% to $5.9 million in 2024, then decreased by 13.19% to $5.1 million in 2025.
  • Its Accumulated Expenses was $5.1 million in Q3 2025, compared to $5.0 million in Q2 2025 and $3.3 million in Q1 2025.